128 related articles for article (PubMed ID: 26142492)
1. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
[TBL] [Abstract][Full Text] [Related]
2. Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.
Ouach A; Boulahjar R; Vala C; Bourg S; Bonnet P; Guguen-Guillouzo C; Ravache M; Le Guevel R; Lozach O; Lazar S; Troin Y; Meijer L; Ruchaud S; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2016 Jun; 115():311-25. PubMed ID: 27019296
[TBL] [Abstract][Full Text] [Related]
3. Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Boulahjar R; Ouach A; Matteo C; Bourg S; Ravache M; le Guével R; Marionneau S; Oullier T; Lozach O; Meijer L; Guguen-Guillouzo C; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
J Med Chem; 2012 Nov; 55(22):9589-606. PubMed ID: 23083119
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
5. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors.
Malmström J; Viklund J; Slivo C; Costa A; Maudet M; Sandelin C; Hiller G; Olsson LL; Aagaard A; Geschwindner S; Xue Y; Vasänge M
Bioorg Med Chem Lett; 2012 Sep; 22(18):5919-23. PubMed ID: 22889803
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.
Rzasa RM; Kaller MR; Liu G; Magal E; Nguyen TT; Osslund TD; Powers D; Santora VJ; Viswanadhan VN; Wang HL; Xiong X; Zhong W; Norman MH
Bioorg Med Chem; 2007 Oct; 15(20):6574-95. PubMed ID: 17697781
[TBL] [Abstract][Full Text] [Related]
12. Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
Nair N; Kudo W; Smith MA; Abrol R; Goddard WA; Reddy VP
Bioorg Med Chem Lett; 2011 Jul; 21(13):3957-61. PubMed ID: 21641213
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors.
Kaller MR; Zhong W; Henley C; Magal E; Nguyen T; Powers D; Rzasa RM; Wang W; Xiong X; Norman MH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6591-4. PubMed ID: 19864130
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.
Plisson F; Conte M; Khalil Z; Huang XC; Piggott AM; Capon RJ
ChemMedChem; 2012 Jun; 7(6):983-90. PubMed ID: 22532438
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
[TBL] [Abstract][Full Text] [Related]
16. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
Zhang N; Zhong R; Yan H; Jiang Y
Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
[TBL] [Abstract][Full Text] [Related]
17. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.
Bhat R; Xue Y; Berg S; Hellberg S; Ormö M; Nilsson Y; Radesäter AC; Jerning E; Markgren PO; Borgegård T; Nylöf M; Giménez-Cassina A; Hernández F; Lucas JJ; Díaz-Nido J; Avila J
J Biol Chem; 2003 Nov; 278(46):45937-45. PubMed ID: 12928438
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
[TBL] [Abstract][Full Text] [Related]
19. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.
Tell V; Holzer M; Herrmann L; Mahmoud KA; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2012 Nov; 22(22):6914-8. PubMed ID: 23039927
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
